Moleculin Biotech Inc./$MBRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Ticker
$MBRX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
17
ISIN
US60855D3098
Website
MBRX Metrics
BasicAdvanced
$9.4M
-
-$4.50
1.57
-
Price and volume
Market cap
$9.4M
Beta
1.57
52-week high
$1.41
52-week low
$0.62
Average daily volume
778K
Financial strength
Current ratio
1.354
Quick ratio
1.12
Long term debt to equity
776.19
Total debt to equity
1,071.429
Management effectiveness
Return on assets (TTM)
-62.45%
Return on equity (TTM)
-214.79%
Valuation
Price to book
224.93
Price to tangible book (TTM)
-0.85
Price to free cash flow (TTM)
-0.159
Growth
Earnings per share change (TTM)
-64.56%
3-year earnings per share growth (CAGR)
-22.37%
MBRX News
AllArticlesVideos
Moleculin Participates in Virtual Investor “What This Means” Segment
GlobeNewsWire·2 days ago
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
GlobeNewsWire·1 week ago
Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Moleculin Biotech Inc. stock?
Moleculin Biotech Inc. (MBRX) has a market cap of $9.4M as of June 13, 2025.
What is the P/E ratio for Moleculin Biotech Inc. stock?
The price to earnings (P/E) ratio for Moleculin Biotech Inc. (MBRX) stock is 0 as of June 13, 2025.
Does Moleculin Biotech Inc. stock pay dividends?
No, Moleculin Biotech Inc. (MBRX) stock does not pay dividends to its shareholders as of June 13, 2025.
When is the next Moleculin Biotech Inc. dividend payment date?
Moleculin Biotech Inc. (MBRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Moleculin Biotech Inc.?
Moleculin Biotech Inc. (MBRX) has a beta rating of 1.57. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.